Gaylen M Zentner
Pharmacy in Salt Lake City, UT

License number
Utah 142658-8911
Issued Date
Jan 1, 1911
Expiration Date
Sep 30, 2017
Category
Pharmacy
Type
Pharmacist Controlled Substance
Address
Address
Salt Lake City, UT

Personal information

See more information about Gaylen M Zentner at radaris.com
Name
Address
Phone
Gaylen Zentner, age 72
6312 Colleton Cir, Salt Lake Cty, UT 84121
(801) 898-6593
Gaylen Zentner, age 72
6312 S Colleton Cir, Salt Lake City, UT 84121
(801) 898-6593
Gaylen Zentner
Holladay, UT
(801) 277-5524
Gaylen M Zentner, age 72
1912 Douglas St, Salt Lake City, UT 84105
(801) 466-3523
Gaylen M Zentner, age 72
6312 Colleton Cir, Salt Lake Cty, UT 84121
(801) 277-5524

Professional information

Gaylen Zentner Photo 1

Bioactive Agent Delivering System Comprised Of Microparticles Within A Biodegradable To Improve Release Profiles

US Patent:
6589549, Jul 8, 2003
Filed:
Jul 13, 2001
Appl. No.:
09/906041
Inventors:
Chung Shih - Salt Lake City UT
Gaylen Zentner - Salt Lake City UT
Assignee:
Macromed, Incorporated - Sandy UT
International Classification:
A61F 200
US Classification:
424426, 424486, 424489, 424501, 5147723
Abstract:
A composition and method for releasing a bio-active agent or a drug within a biological environment in a controlled manner is disclosed. The composition is a dual phase polymeric agent—delivery composition comprising a continuous biocompatible gel phase, a discontinuous particulate phase comprising defined microparticles and an agent to be delivered. A microparticle containing a bio-active agent is releasably entrained within a biocompatible polymeric gel matrix. The bioactive agent release may be contained in the microparticle phase alone or in both the microparticles and the gel matrix. The release of the agent is prolonged over a period of time, and the delivery may be modulated and/or controlled. In addition, a second agent may be loaded in some of the microparticles and/or the gel matrix.


Gaylen Zentner Photo 2

Vp Cmc R&Amp;D Myrexis, Inc. (Formerly Myriad Pharmaceuticals, Inc.)

Position:
VP Chemistry, Manufacturing, and Controls Research and Development at Myrexis, Inc.
Location:
Greater Salt Lake City Area
Industry:
Pharmaceuticals
Work:
Myrexis, Inc. since Apr 2002 - VP Chemistry, Manufacturing, and Controls Research and Development MacroMed, Inc. Aug 1997 - Apr 2002 - Executive Vice President, Pharmaceutical Research and Development Sarcos Feb 1995 - Aug 1997 - Director, Drug Delivery Merck & Co. Jun 1987 - Feb 1995 - Director, Controlled Release (INTERx Division)
Education:
University of Utah 1975 - 1979
PhD, Pharmaceutics


Gaylen Zentner Photo 3

Vice President At Myriad Pharmaceuticals, Inc

Location:
Greater Salt Lake City Area
Industry:
Pharmaceuticals


Gaylen Zentner Photo 4

Polymer Blends That Swell In An Acidic Environment And Deswell In A Basic Environment

US Patent:
6730327, May 4, 2004
Filed:
Dec 20, 2002
Appl. No.:
10/327457
Inventors:
Gaylen M. Zentner - Salt Lake City UT
Jong-Seok Bark - Salt Lake City UT
Feng Liu - Salt Lake City UT
Assignee:
MacroMed, Inc. - Sandy UT
International Classification:
A61K 914
US Classification:
424489, 424484, 424486, 424488, 424499, 424501, 514772, 5147721, 5147722, 5147723
Abstract:
A polymer blend is prepared by dissolving chitosan and a second polymer in an acidic aqueous solution to form an aqueous polymer blend, dehydrating said aqueous polymer blend, and recovering said polymer blend. The second polymer may be selected from the group consisting of polyether glycols including polyethylene glycols; cellulose esters including cellulose acetate; poloxamers; polysaccharides including dextran and guar; polyvinylpyrrolidones; polyvinyl alcohols; and mixtures or copolymers thereof. These polymer blends swell in an acidic environment and deswell in a more neutral or basic environment. This technology is valuable for the dispensing of biologically active material or drugs into a surrounding environment, especially the environment as is found in the gastrointestinal tract. Since the various polymer blends of the present invention are not covalently or ionically crosslinked, but are physically combined, each polymer in the physical blend maintains its original chemical structure, and therefore, is safe for oral administration.


Gaylen Zentner Photo 5

Pla/Plga Oligomers Combined With Block Copolymers For Enhancing Solubility Of A Drug In Water

US Patent:
6592899, Jul 15, 2003
Filed:
Oct 3, 2001
Appl. No.:
09/971082
Inventors:
Kirk Dee Fowers - Layton UT
Gaylen M. Zentner - Salt Lake City UT
Chung Shih - Sandy UT
Assignee:
Macromed Incorporated - Sandy UT
International Classification:
A61K 914
US Classification:
424486, 424426, 424444, 424430, 424434, 424449, 424484, 525411, 525413, 525415
Abstract:
Polymeric compositions having improved capability of solubilizing a drug in a hydrophilic environment to form a solution, comprising: a biodegradable polyester oligomer; and biodegradable AB-type, ABA-type, or BAB-type block copolymers are disclosed. The copolymers are comprised of about 50. 1 to 65% by weight of a biodegradable, hydrophobic A polymer block comprising a biodegradable polyester, and about 35 to 49. 9% by weight of a hydrophilic B polymer block comprising a polyethylene glycol (PEG), and wherein the block copolymer has a weight averaged molecular weight of between 2400 to 4999. The biodegradable polyester oligomer of said composition is within a range of 0. 01% to 30% by weight of the total polymer mixture, and the content of the biodegradable AB-type, ABA-type, or BAB-type block copolymer is within a range of 70% to 99. 99% by weight of the total polymer mixture.


Gaylen Zentner Photo 6

Biodegradable Low Molecular Weight Triblock Poly (Lactide-Co-Glycolide) Polyethylene Glycol Copolymers Having Reverse Thermal Gelation Properties

US Patent:
6117949, Sep 12, 2000
Filed:
Oct 1, 1998
Appl. No.:
9/164865
Inventors:
Ramesh C. Rathi - Salt Lake City UT
Gaylen M. Zentner - Salt Lake City UT
Assignee:
Macromed, Inc. - Salt Lake City UT
International Classification:
C08G 6391, C08L 6700
US Classification:
525415
Abstract:
A water soluble biodegradable ABA- or BAB-type triblock polymer is disclosed that is made up of a major amount of a hydrophobic polymer made of a poly(lactide-co-glycolide) copolymer or poly(lactide) polymer as the A-blocks and a minor amount of a hydrophilic polyethylene glycol polymer B-block, having an overall weight average molecular weight of between about 2000 and 4990, and that possesses reverse thermal gelation properties. Effective concentrations of the triblock polymer and a drug may be uniformly contained in an aqueous phase to form a drug delivery composition. At temperatures below the gelation temperature of the triblock polymer the composition is a liquid and at temperatures at or above the gelation temperature the composition is a gel or semi-solid. The composition may be administered to a warm-blooded animal as a liquid by parenteral, ocular, topical, inhalation, transdermal, vaginal, transurethral, rectal, nasal, oral, pulmonary or aural delivery means and is a gel at body temperature. The composition may also be administered as a gel.


Gaylen Zentner Photo 7

Biodegradable Triblock Copolymers As Solubilizing Agents For Drugs And Method Of Use Thereof

US Patent:
2004018, Sep 23, 2004
Filed:
Dec 11, 2003
Appl. No.:
10/734740
Inventors:
Chung Shih - Sandy UT, US
Gaylen Zentner - Salt Lake City UT, US
Kirk Fowers - Layton UT, US
Assignee:
MacroMed, Incorporated.
International Classification:
A61K009/14
US Classification:
424/486000
Abstract:
Biodegradable ABA-type or BAB-type triblock copolymers are disclosed that, at functional concentrations, are capable of solubilizing drugs, especially hydrophobic drugs, in a hydrophilic environment to form a solution at temperatures relevant for parenteral and particularly for intravenous administration as well as all other routes of administration benefiting from an aqueous drug solution. The copolymers are comprised of about 50.1 to 65% by weight of biodegradable hydrophobic A polymer block(s) comprising a biodegradable polyester, and about 35 to 49.9% by weight of a biodegradable hydrophilic B polymer block comprising a polyethylene glycol (PEG), and wherein the triblock copolymer has a weight-averaged molecular weight of between about 1500 to 3099 Daltons.


Gaylen Zentner Photo 8

Reconstitutable Compositions Of Biodegradable Block Copolymers

US Patent:
2003022, Dec 11, 2003
Filed:
Jun 11, 2002
Appl. No.:
10/167768
Inventors:
Chung Shih - Sandy UT, US
Gaylen Zentner - Salt Lake City UT, US
International Classification:
A61K009/14
US Classification:
424/486000
Abstract:
A composition having enhanced reconstitution properties and method of use is disclosed. The composition comprises one or more biodegradable block copolymer drug carriers; and a reconstitution enhancing and enabling agent comprising polyethylene glycol (PEG), a PEG derivative or a mixture of PEG and a PEG derivative; and wherein the biodegradable block copolymer drug carrier is soluble in an aqueous solution and in the liquid reconstitution enhancing and enabling agent.


Gaylen Zentner Photo 9

Biodegradable Block Copolymeric Compositions For Drug Delivery

US Patent:
2010007, Mar 25, 2010
Filed:
Nov 30, 2009
Appl. No.:
12/627175
Inventors:
Chung Shih - Sandy UT, US
Gaylen M. Zentner - Salt Lake City UT, US
International Classification:
A61K 47/30, A61K 31/337, A61P 35/00
US Classification:
514449, 5147721
Abstract:
An improved drug delivery composition and method of use is disclosed. The composition comprises one or more biodegradable block copolymer drug carriers; and a reconstitution enhancing and enabling agent comprising polyethylene glycol (PEG), a PEG derivative or a mixture of PEG and a PEG derivative. The composition can be administered as is or after being be dissolved or rapidly reconstituted in an aqueous vehicle to afford a homogeneous solution or uniform colloidal systems.


Gaylen Zentner Photo 10

High Drug Load Formulations And Dosage Forms

US Patent:
2011011, May 12, 2011
Filed:
Apr 30, 2010
Appl. No.:
12/771621
Inventors:
Gaylen M. Zentner - Salt Lake City UT, US
James C. McRea - Salt Lake City UT, US
Mark S. Williams - Salt Lake City UT, US
Tracy Annette Powers - Saint Louis MO, US
Assignee:
Myriad Pharmaceuticals, Inc. - Salt Lake City UT
International Classification:
A61K 31/192, A61K 9/28, A61P 25/28
US Classification:
424465, 514570
Abstract:
The invention relates to high drug load formulations containing (R)-2-(2-fluoro-4-biphenylyl)propionic acid as an active pharmaceutical ingredient.